美托洛尔联合曲美他嗪对冠心病心力衰竭患者炎症因子及心功能的影响

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (0 KB) HTML (35 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨美托洛尔联合曲美他嗪对冠心病心力衰竭患者炎症因子及心功能的影响。方法选取2016年7月～2018年6月九江市第一人民医院心内科收治的104 例冠心病心力衰竭患者作为研究对象，按照随机数字表法分为对照组（52 例）和观察组（52 例）。对照组采用美托洛尔治疗，观察组采用美托洛尔联合曲美他嗪治疗。比较两组的临床治疗效果、治疗前后的炎症因子水平和心功能指标及不良反应总发生率。结果观察组的治疗总有效率高于对照组，差异有统计学意义（P＜0.05）。两组治疗后的肿瘤坏死因子-α（TNF-α）、白介素-6（IL-6）、超敏C 反应蛋白（hs-CRP）水平低于治疗前，观察组治疗后的TNF-α、IL-6 和hs-CRP 水平低于对照组，差异均有统计学意义（P＜0.05）。两组治疗后的左室射血分数（LVEF）高于治疗前，左室收缩末期内径（LVESD）、左室舒张末期内径（LVEDD）低于治疗前，观察组治疗后的LVEF 高于对照组，LVESD、LVEDD 低于对照组，差异均有统计学意义（P＜0.05）。两组的不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论冠心病心力衰竭患者行美托洛尔联合曲美他嗪治疗可有效提高治疗效果，改善心功能，降低炎症因子水平，值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	汤曾耀
	刘继文
	王新旺
	朱保成
	刘玉连

关键词 ：冠心病心力衰竭, 美托洛尔, 曲美他嗪, 炎症因子, 心功能

Abstract：Objective To investigate the effect of Metoprolol combined with Trimetazidine on inflammatory factors and cardiac function in patients with coronary heart disease and heart failure. Methods A total of 104 patients with coronary heart disease and heart failure who were admitted to the Department of Cardiology, Jiujiang First People′s Hospital from July 2016 to June 2018 were selected as the research objects, they were divided into control group (52 cases)and observation group (52 cases) according to the random number table method. The control group was treated with Metoprolol, and the observation group was treated with Metoprolol combined with Trimetazidine. The clinical treatment effect, inflammatory factor levels and cardiac function indexes before and after treatment, and total incidence of adverse reactions were compared between the two groups. Results The total effective rate in the observation group was higher than that in the control group, the difference was statistically significant (P＜0.05). The levels of tumor necrosis factor-α(TNF-α), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP) in the two groups after treatment were lower than those before treatment, the levels of TNF-α, IL-6 and hs-CRP in the observation group after treatment were lower than those in the control group, the differences were statistically significant (P＜0.05). After treatment, the left ventricular ejection fraction (LVEF) in the two groups was higher than that before treatment, the left ventricular endsystolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) were lower than those before treatment,the LVEF after treatment in the observation group was higher than that in the control group, and LVESD and LVEDD were lower than those in the control group, the differences were statistically significant (P＜0.05). There was no significant difference in the overall incidence of adverse reactions between the two groups (P＞0.05). Conclusion The treatment of patients with coronary heart disease and heart failure with Metoprolol combined with Trimetazidine can effectively improve the treatment effect, improve cardiac function, and reduce the level of inflammatory factors, which is worthy of clinical application.

Key words： Coronary heart disease and heart failure;Metoprolol Trimetazidine Inflammatory factor Cardiac function

作者简介: 汤曾耀（1987-），男，江西九江人，硕士，主治医师，研究方向：冠心病的诊治

引用本文:

汤曾耀；刘继文；王新旺；朱保成；刘玉连. 美托洛尔联合曲美他嗪对冠心病心力衰竭患者炎症因子及心功能的影响[J]. 中国当代医药, 2020, 27(7): 48-50转54.
TANG Zeng-yao； LIU Ji-wen； WANG Xin-wang； ZHU Bao-cheng； LIU Yu-lian. Effect of Metoprolol combined with Trimetazidine on inflammatory factors and cardiac function in patients with coronary heart disease and heart failure. 中国当代医药, 2020, 27(7): 48-50转54.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I7/48

[1]	李毅，冯艳林，马瑞，等.美托洛尔结合曲美他嗪对冠心病心力衰竭患者临床疗效及血浆脑钠肽的影响研究[J].中国心血管病研究，2018，16（8）：740-742.
[2]	陶智军.曲美他嗪联合美托洛尔治疗冠心病心力衰竭对血管内皮功能及氧化应激指标的影响[J].中国临床医生杂志，2018，46（6）：667-670.
[3]	郭继芳，游陆，李作武.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的疗效及对血浆脑钠肽水平的影响[J].中国医院用药评价与分析，2017，17（8）：1047-1048，1051.
[4]	中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心血管疾病预防指南[J].中华心血管病杂志，2011，41（1）：538-539.
[5]	中华医学会心血管病学分会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志，2007，35（12）：1076-1095.
[6]	朱凌华，朱明真.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭的临床效果[J].中国当代医药，2018，25（29）：43-45.
[7]	黄健雄.美托洛尔联合曲美他嗪在冠心病心力衰竭治疗中的应用[J].中国基层医药，2017，24（14）：2203-2206.
[8]	郭峰，周乃珍.曲美他嗪片治疗冠心病心力衰竭的临床研究[J].中国临床药理学杂志，2017，33（15）：1406-1408.
[9]	强永在，高喜源.美托洛尔联合曲美他嗪治疗冠心病伴心力衰竭50 例效果观察[J].内蒙古医科大学学报，2018，40（4）：415-416，422.
[10]	刘廷怡，刘瑶，王安伟.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效[J].解放军预防医学杂志，2018，36（6）：713-716.
[11]	顾丽萍，胡菁，严蜀华.美托洛尔与曲美他嗪治疗老年冠心病心力衰竭的疗效及对患者心功能、心肌重塑和炎症因子的影响[J].中国老年学杂志，2017，37（1）：89-91.
[12]	游云起.美托洛尔联合曲美他嗪对冠心病心力衰竭患者血浆脑钠肽水平及心功能的影响[J].山西医药杂志，2018，47（17）：2085-2087.
[13]	陈红光，卢杰，付鑫，等.美托洛尔辅助治疗老年冠心病心力衰竭的疗效及对机体炎性应激及免疫功能的影响[J].实用老年医学，2018，32（9）：873-876.
[14]	李堪董，赵圣吉，史丽.曲美他嗪联合美托洛尔治疗老年冠心病合并心力衰竭的临床研究[J].中国临床药理学杂志，2018，34（5）：507-510.
[15]	康晓洁，白春林.美托洛尔联合曲美他嗪治疗冠心病心力衰竭疗效分析[J].中国药物与临床，2018，18（12）：2206-2207.